How safe is Cosentyx for long-term use?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions, shows sustained efficacy and a consistent safety profile in studies up to 5 years. Pooled data from phase 3 trials and extensions report serious adverse events at rates of 5-10% annually, similar to shorter-term use, with no new safety signals emerging over time.[1][2]
Common side effects include upper respiratory infections (15-20%), diarrhea (5-10%), and nasopharyngitis. Long-term monitoring highlights stable rates of these, without dose-dependent increases.[3]
What do long-term clinical trials show?
In the FUTURE 5 extension (up to 5 years), 70-80% of psoriasis patients maintained PASI 90 responses, with exposure-adjusted infection rates of 1.5-2.0 per patient-year. Serious infections occurred in 0.7-1.2% yearly, comparable to placebo in early trials. No increased malignancy or tuberculosis risk beyond baseline appeared after 2,500+ patient-years.[2][4]
SCRIPPS and CLEAR open-label extensions (4-5 years) confirm low dropout due to adverse events (under 5%), with immunogenicity (anti-drug antibodies) in 20-30% but rarely neutralizing or linked to loss of response.[1]
What infections and risks concern doctors most?
Long-term users face heightened infection risk, especially candidiasis (3-5% yearly) due to IL-17 blockade. TB screening is required pre-treatment, with rare reactivations (0.1-0.3%). Inflammatory bowel disease (IBD) flares or new onset occur in 1-2%, prompting avoidance in Crohn's patients.[3][5]
MACE (major adverse cardiovascular events) rates stay low (0.2-0.5% per year), aligned with disease-matched populations. No excess cancer signal in registries like BADBIR (up to 3 years).[4]
Can it be used in special populations long term?
Pregnancy data is limited; animal studies show no harm, but human registries advise contraception during treatment and 20 weeks post-dose. Lactation transfer is minimal. Pediatrics (ages 6+) have 2-year data showing similar safety to adults.[3][6]
Elderly patients (>65) have higher infection rates but no adjusted contraindications beyond standard monitoring.
How does monitoring work for long-term patients?
Annual TB tests, vaccination updates (e.g., pneumococcal, shingles), and IBD screening are standard. Liver/kidney function checks occur if indicated. Novartis guidelines recommend continuing if benefits outweigh risks, with 80% of trial patients on therapy beyond 3 years.[5][7]
Discontinuation is rare (<10% for safety) unless active infection or IBD develops.
What do real-world patients report?
Patient registries and forums note good tolerability, with 60-70% continuing 2+ years. Common complaints: mild infections or injection-site reactions fading over time. Some switch due to cost or convenience, not safety.[4][8]
[1]: Novartis Cosentyx Prescribing Information
[2]: Langley RG et al. J Am Acad Dermatol 2020;83:1087-97
[3]: FDA Label Update 2023
[4]: Griffiths CE et al. Br J Dermatol 2022;187:567-75
[5]: EULAR Recommendations 2023
[6]: Deodhar A et al. Lancet 2022;399:27-39
[7]: Novartis Safety Update 2024
[8]: BADBIR Registry Annual Report 2023